Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240381 · ClinicalTrials.gov registry record · NA
Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT02240381 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 22 participants.
The verdict
NCT02240381, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This clinical trial studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. Oral glucose tolerance testing (OGTT), euglycemic hyperinsulinemic clamps, and immune assays will be used to define the mechanisms associated with abnormal glucose homeostasis following stem cell transplantation. Information from this clinical trial could be used to develop standardized screening procedures or to develop optimal treatment strategies for patients developing post-transplant diabetes mellitus.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-11-20 |
| Est. Completion | 2019-01-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02240381
The ClinicalTrials.gov registry entry for NCT02240381 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02240381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02240381 about?
NCT02240381 is a clinical study titled "Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant". This clinical trial studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. Oral glucose tolerance testing (OGTT), euglycemic hyperinsulinemic clamps, and immune assays will be used to define the mechanisms ass...
What is the current status of trial NCT02240381?
This trial is currently terminated. It is a NA study. The enrollment target is 22 participants. The study started on 2014-11-20. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT02240381?
The interventions under investigation include: laboratory biomarker analysis (OTHER), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT02240381?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.